NImmune Biopharma and BioTherapeutics, Inc. Partner on Inflammation and Immunology Precision Medicines

NImmune Biopharma, a company at the forefront of precision immunology and biopharmaceuticals, has entered into a research collaboration with BioTherapeutics, Inc. This partnership aims to enhance NImmune’s capabilities by utilizing BioTherapeutics’ advanced preclinical services, regulatory expertise, and unique animal models for the study of inflammatory and autoimmune diseases.

The collaboration will provide NImmune with access to BioTherapeutics’ proprietary disease models, including innovative pig models for inflammatory bowel disease (IBD), along with capabilities in pharmacokinetics/pharmacodynamics (PK/PD) analysis and regulatory procedures. This partnership is expected to bolster the development, testing, and validation of NImmune’s pipeline of immunoregulatory therapeutics.

Dr. Raquel Hontecillas, the Chief Scientific Officer at BioTherapeutics, emphasized the importance of this collaboration. She highlighted that BioTherapeutics’ sophisticated computational and preclinical services, especially their proprietary animal models, would support the creation of much-needed therapies. BioTherapeutics operates within a dynamic drug development ecosystem in Blacksburg, enabling the rapid development of safer and more effective therapeutics.

NImmune’s CEO, Dr. Josep Bassaganya-Riera, expressed that the partnership with BioTherapeutics is a significant extension of their research and development ecosystem. This ecosystem is designed to facilitate the creation of innovative immunoregulatory therapeutics to address the unmet clinical needs of patients suffering from inflammatory and autoimmune diseases. He also noted that the collaboration with BioTherapeutics complements an existing partnership with the NIMML Institute, further enhancing their capacity for scientific innovation and development from discovery to commercialization.

The collaboration has already demonstrated significant clinical and commercial success, notably in the development of NX-13 and its acquisition by AbbVie, Inc. This success is a testament to the efficacy of the combined capabilities of BioTherapeutics and the NIMML Institute.

Dr. Bassaganya-Riera further elaborated on the strategic importance of the partnership, stating that it brings together BioTherapeutics’ validated models with NImmune’s expertise in translating fundamental discoveries into effective medicines for immune-mediated diseases like ulcerative colitis, Crohn’s disease, psoriasis, rheumatoid arthritis, asthma, and systemic lupus erythematosus. He is optimistic about the potential for this ongoing collaboration to significantly accelerate the clinical development of NImmune’s drug candidates.

NImmune Biopharma is a precision immunology biopharmaceutical company that focuses on developing novel, biomarker-driven immunoregulatory therapeutics. The company leverages a discovery platform that integrates advanced computational modeling, artificial intelligence (AI), and bioinformatics with biomedical research. This approach facilitates the rapid and efficient clinical development of promising drug candidates, aiming towards New Drug Application (NDA) filings and commercialization.

Their lead product candidate, omilancor, is a Phase 3-ready, oral, once-daily therapeutic targeting LANCL2 for the treatment of Ulcerative Colitis and Crohn’s disease. Omilancor has shown potential best-in-class efficacy and safety in Phase 2 trials, with registration-directed pivotal clinical trials scheduled for the second half of 2023.

BioTherapeutics, Inc., a clinical-stage biotech company, combines advanced computational modeling with translational and clinical experimentation to accelerate the development of novel precision medicine products. The company is based in Blacksburg, VA, and is dedicated to advancing healthcare through the synergistic integration of technology and clinical research.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!